GLP-1R is known to play a key role in controlling blood sugar levels by enhancing glucose-stimulated insulin secretion. Therefore, there is considerable interest in harnessing regulation of the GLP-1R mediated signaling pathway as a therapeutic approach to type 2 diabetes, which has already resulted in the development of several GLP-1 FDA-approved agonists. In addition, GLP-1R agonists have also been shown to contribute to weight management, decrease the potential for cardiovascular diseases and protect pancreatic beta cells.

This new GLP-1R / CRE Luciferase Reporter HEK293 cell line has been engineered to monitor activation of GLP-1R in cells by measuring luciferase activity, making it useful for cell-based binding assays and screening for human GLP-1R agonists. The functionality of AMSBIO’s new GLP-1R/CRE Luciferase Reporter HEK293 Cell line has been validated in dose-response assays using both peptide and small molecule agonists.

Get training in Lab Crisis Preparation and earn CEUs.

One of over 25 IACET-accredited courses in the Academy.

Lab Crisis Preparation course

To complement this reporter cell line—AMSBIO has also launched gastric inhibitory polypeptide receptor (GIPR) and glucagon receptor (GCGR) reporter cell lines. Along with GLP-1R, these receptors are critical for regulating blood sugar levels. Dual agonists that bind both GIPR/GCGR and GLP-1R show promising results for the treatment of type 2 diabetes and obesity. Therefore, together these cell lines provide a powerful platform for screening of combination therapies by measuring the activity of co-stimulatory targets in response to agonists.